 |
|
An Overview of the Efficacy and Safety of Fenfluramine and Mazindol in the Treatment of Obesity
Keith A. Stahl, MD;
Thomas F. Imperiale, MD
Arch Fam Med. 1993;2(10):1033-1038.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Gray DS. Diagnosis and prevalence of obesity. Med Clin North Am. 1989;73:1-13.
PUBMED
2. NIH Conference. Gastrointestinal surgery for severe obesity. Ann Intern Med. 1991;115:956-961.
FREE FULL TEXT
3. Hirsch J. Barriers to treating obesity. Ann Intern Med. 1991;115:656.
FREE FULL TEXT
4. Elliot DL, Goldbert L. Barriers to treating obesity. Ann Intern Med. 1991;115:656-657.
FREE FULL TEXT
5. Bray GA. Barriers to the treatment of obesity. Ann Intern Med. 1991;115:152-153.
FREE FULL TEXT
6. Der Simonian R, Laird N. Combining evidence in clinical trials. Controlled Clin Trials. 1986;7:177-188.
PUBMED
7. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. Orlando, Fla: Academic Press; 1985. 8. Maclay W, Wallace M. A multi-centre general practice trial of mazindol in the treatment of obesity. Practitioner. 1977;218:431-434.
PUBMED
9. Brun L, Bielmann P, Gagne C, Moorjani S, Nadeau A, Lupien PJ. Effects of fenfluramine in hypertriglyceridemic obese subjects. Int J Obes. 1988;12:423-431.
PUBMED
10. Goldrick R, Nestel P, Havenstein N. Comparison of a new anorectic agent AN448 with fenfluramine in the treatment of refractory obesity. Med J Aust. 1974;1:882-885.
PUBMED
11. Sedgwick J. Mazindol in the treatment of obesity. Practitioner. 1975;214:418-420.
PUBMED
12. Tisdale S, Ervin D. Anorectic effectiveness of differing dosage forms of fenfluramine. Curr Ther Res. 1976;19:589-594.
PUBMED
13. Smith R, Innes J, Munro JF. Double-blind evaluation of mazindol in refractory obesity. BMJ. 1975;3:284.
FREE FULL TEXT
14. Wallace A. AN448 Sandoz (mazindol) in the treatment of obesity. Med J Aust. 1976;1:343-345.
PUBMED
15. Weintraub M, Sriwatanakul K, Sundaresan P, Weis OF, Dorn M. Extendedrelease fenfluramine: patient acceptance and efficacy of evening dosing. Clin Pharmacol Ther. 1983;33:621-627.
PUBMED
16. Smith D. A new anorexiant: clinical evaluation. Rocky Mountain Med J. 1974;71:41-44.
PUBMED
17. Walker B, Ballard I, Gold J. A multicentre study comparing mazindol and placebo in obese patients. J Int Med Res. 1977;5:85-90.
PUBMED
18. Steel J, Munro J, Duncan L. A comparative trial of different regimens of fenfluramine and phentermine in obesity. Practitioner. 1973;211:232-236.
PUBMED
19. Thorpe P, Isaac P, Rodgers J. A controlled trial of mazindol (sanorex, teronac) in the management of the obese rheumatic patients. Curr Ther Res. 1975;17:149-155.
PUBMED
20. Elmaleh M, Miller J. Controlled clinical evaluation of a new anorectic agent in obese adults. Pa Med. 1974;77:46-50.
PUBMED
21. Munro J, Seaton D, Duncan L. Treatment of refractory obesity with fenfluramine. BMJ. 1966;2:624-625.
FREE FULL TEXT
22. Heber A. Double-blind trial of mazindol in overweight patients. Med J Aust. 1975;2:566-567.
PUBMED
23. Woodhouse S, Nye ER, Anderson K, Rawlings J. A double-blind controlled trial of a new anorectic agent AN448. NZ Med J. 1975;81:546-549.
PUBMED
24. Vernace B. Controlled comparative investigation of mazindol, D-amphetamine, and placebo. Obes/Bariatr Med. 1974;3:124-129.
25. Schwartz L. A non-amphetamine anorectic agent: preclinical background and a double-blind clinical trial. J Int Med Res. 1975;3:328-332.
26. Stunkard A, Rickels K, Hesbacker P. Fenfluramine in the treatment of obesity. Lancet. 1973;1:503-505.
PUBMED
27. Persson I, Anderson U, Deckert T. Treatment of obesity with fenfluramine. Eur J Clin Pharmacol. 1973;6:93-97.
PUBMED
28. Galloway D, Logie A, Petrie J. Prolonged-action fenfluramine in non-diabetic patients with refractory obesity. Postgrad Med J. 1975;51(suppl):155-157.
PUBMED
29. Sainani G, Fulambarkar A, Khurana B. A double-blind clinical trial of fenfluramine in the treatment of obesity. Br J Clin Pract. 1973;27:136-138.
PUBMED
30. Follows O. A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. Br J Clin Pract. 1971;25:236-238.
PUBMED
31. Maneksha S. Prolonged-action fenfluramine capsules versus fenfluramine tablets in general practice. Br J Clin Pract. 1975;29:12-13.
PUBMED
32. Owen J. Prolonged action fenfluramine in general practice. Br J Clin Pract 1975;29:13-14.
PUBMED
33. Traherne J. A clinical trial of fenfluramine. Practitioner. 1965;195:677-680.
PUBMED
34. Lele R, Joshi V, Nathwani A. A double-blind clinical trial of fenfluramine. Br J Clin Pract. 1972;26:79-82.
PUBMED
35. Haugen H. Double blind cross-over study of a new appetite suppressant AN448. Eur J Clin Pharmacol. 1975;8:71-74.
PUBMED
36. Miach P, Thomson W, Doyle AE, Louis WJ. Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients. Med J Aust. 1976;2:378-380.
PUBMED
37. Hossain M, Campbell D. Fenfluramine and methylcellulose in the treatment of obesity: the relationship between plasma drug concentrations and therapeutic efficacy. Postgrad Med J. 1975;51(suppl):178-182.
FREE FULL TEXT
38. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144:1143-1148.
FREE FULL TEXT
39. Kornhaber A. Obesity-depression: clinical evaluation with a new anorexigenic agent. Psychosomatics. 1973;14:162-167.
FREE FULL TEXT
40. Lawson A, Roscoe P, Strong J, Gibson A, Peattie P. Comparison of fenfluramine and metformin in treatment of obesity. Lancet. 1970;2:437-441.
PUBMED
41. Cameron DC, Kennedy WP, Samuel PD, Crompton GK. Fenfluramine in corticosteroid-induced obesity. Curr Med Res Opin. 1972;1:153-158.
PUBMED
42. Douglas JG, Preston PG, Haslett C, et al. Long term efficacy of fenfluramine in treatment of obesity. Lancet. 1983;1:384-386.
PUBMED
43. Tomlinson S, Lines J, Greenfield MAM. The effect of fenfluramine on obesity and plasma lipids of patients with renal allografts. Postgrad Med J. 1975;51(suppl):166-170.
FREE FULL TEXT
44. Innes JA, Campbell IW, Millar J, Munro JF. A comparison of the efficacy and acceptability of fenfluramine tablets (BP) and prolonged action capsules. Post-grad Med J.J. 1975;51(suppl):160-162.
45. Adadevoh B. Therapeutic effect of fenfluramine in obese Nigerians: clinical, metabolic, and hypotensive properties. Postgrad Med J. 1975;51(suppl):158. Abstract.
PUBMED
46. Balasse EO, Couturier E, Kornitzer M, Degre S. Influence of a long acting preparation of fenfluramine on body weight, body composition and skinfold thickness in obese subjects. Postgrad Med J. 1975;51(suppl):157. Abstract.
PUBMED
47. Gaind R. Fenfluramine (Ponderax) in the treatment of obese psychiatric outpatients. Br J Psychiatry. 1969;115:963-964.
FREE FULL TEXT
48. Rosenthal R. The 'file drawer problem' tolerance for null results. Psychol Bull. 1979;86:638-641.
49. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. BMJ. 1981;283:881-883.
FREE FULL TEXT
50. Pouwels HM, Smeets JL, Cheriex EC, Wouters EF. Pulmonary hypertension and fenfluramine. Eur Respir J. 1990;3:606-607.
ABSTRACT
51. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. BMJ. 1986;292:239-240.
FREE FULL TEXT
|
